| Name | Title | Contact Details |
|---|
Through safe agricultural, home and garden products and technologies, Westbridge is cultivating environmental awareness.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
SeraCare Life Sciences, Inc. is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marina Biotech is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.